Drug manufacturer Novo Nordisk has amended its policy restrictions on 340B drug sales to hospitals involving shipments to contract pharmacies.
In a notice to covered entities dated Jan. 24, Novo Nordisk said if a 340B hospital covered entity “does not have wholly owned contract pharmacies, that covered entity will be permitted to designate a total of two contract pharmacy locations—one retail pharmacy, and one specialty pharmacy (as determined by Novo Nordisk)—to which product purchased by that covered entity may be shipped.” It previously let hospitals designate just one contract pharmacy. The policy change takes effect Feb. 1.
Drug manufacturer Novo Nordisk has amended its policy restrictions on 340B drug sales to hospitals involving shipments to contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
